Zelira Therapeutics (AU:ZLD) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zelira Therapeutics Ltd, a pioneer in clinically validated cannabinoid-based medicines, is set to provide an investor webinar update on its FDA progress and future plans for its HOPE product line. The company, which is actively engaged in advanced clinical trials and commercialization of products for various medical conditions, will also discuss the commercialization of its ZENIVOL product in Germany and its revenue-generating OTC products.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.